MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Stereotaxis EBITDA 2011-2026 | STXS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Stereotaxis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.5 M | -24.2 M | -21.2 M | -18.3 M | -12.8 M | -6.59 M | -4.7 M | -1.88 M | -5.17 M | -5.86 M | -4.79 M | -4.67 M | -7.62 M | -9.03 M | -30.2 M | -17.3 M | -21.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.88 M | -30.2 M | -12.8 M |
Quarterly EBITDA Stereotaxis
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.82 M | - | - | -5.77 M | - | - | -4.61 M | - | - | -5.46 M | - | -4.75 M | -4.98 M | -3.99 M | - | -4.54 M | -3.34 M | -1.5 M | - | -1.48 M | -1.86 M | -2.02 M | - | 47.6 K | -1.4 M | -2.11 M | - | 280 K | -344 K | -990 K | - | 581 K | -157 K | -1.76 M | - | -898 K | -1.45 M | -1.39 M | - | -684 K | -1.59 M | -1.34 M | - | -845 K | -2.05 M | -2.09 M | - | -363 K | -1.26 M | -3.33 M | - | 55 K | -3.97 M | -3.83 M | - | -7.96 M | -8.81 M | -8.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 581 K | -8.81 M | -2.66 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
1.06 B | $ 60.58 | 0.33 % | $ 12.1 B |  USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 115.46 | 1.14 % | $ 3.7 B | USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
ICU Medical
ICUI
|
244 M | $ 120.37 | -2.13 % | $ 2.97 B | USA |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 3.87 | -2.76 % | $ 179 M | USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 421.73 | -1.48 % | $ 151 B | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 97.52 | -1.99 % | $ 2.21 B | USA |
 |
Alcon
ALC
|
580 M | $ 63.93 | -0.14 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
-164 M | $ 178.4 | 0.03 % | $ 9.51 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 23.69 | -0.67 % | $ 3.98 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
-12.7 M | $ 6.29 | -2.18 % | $ 53.4 K | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 56.6 | -0.86 % | $ 2.85 B | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 32.27 | 0.81 % | $ 1.6 B | USA |
 |
STERIS plc
STE
|
1.34 B | $ 214.08 | -0.88 % | $ 21.1 B | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 128.92 | -1.04 % | $ 5.75 B | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 141.43 | -0.52 % | $ 6.85 B | USA |
 |
InfuSystem Holdings
INFU
|
25.2 M | $ 8.57 | -0.46 % | $ 177 M | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 1.93 | 4.32 % | $ 88.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
-5.62 M | $ 0.33 | -1.64 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 62.4 | -0.26 % | $ 3.69 B | USA |
 |
Utah Medical Products
UTMD
|
12.2 M | $ 63.24 | -0.72 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 301.39 | 0.4 % | $ 21.8 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 24.12 | -11.01 % | $ 1.63 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 10.04 | -3.6 % | $ 2 B | USA |
 |
Retractable Technologies
RVP
|
-13.4 M | $ 0.69 | - | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 59.95 | 2.22 % | $ 197 M | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
-14.3 M | $ 20.55 | -2.42 % | $ 981 M | USA |
 |
Baxter International
BAX
|
673 M | $ 17.32 | -2.64 % | $ 8.89 B | USA |
 |
ResMed
RMD
|
1.16 B | $ 202.53 | -0.01 % | $ 29.6 B | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 28.37 | 0.79 % | $ 1.35 B | USA |
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 5.36 | -2.9 % | $ 238 M | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 10.88 | -1.36 % | $ 444 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 142.79 | -1.2 % | $ 41.1 B | USA |
 |
Nephros
NEPH
|
1.29 M | $ 3.16 | -5.39 % | $ 33.5 M | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 3.08 | 4.24 % | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
134 M | $ 105.36 | 1.91 % | $ 5.92 M | USA |